[Autom. eng. transl.] The introduction of biological drugs has revolutionized the therapeutic approach in Idiopathic Juvenile Systemic Arthritis (SoJIA), modifying the natural history of this disease and improving its overall outcome. The main objective of the study was to analyze the persistence rate in therapy (DRR) of Interleukin (IL) -1 inhibitors in patients with SoJIA. Secondary objectives of the study were: (1) to explore the influence of the biological treatment line, of adverse events, of the specific anti-IL-1 agent and of the treatment with disease modifying anti-rheumatic drugs (cDMARDs) on DRR; (2) identify any predictive factors associated with abandoning the therapy. Demographic, clinical and therapeutic data relating to patients with SoJIA treated with anakinra and canakinumab in 15 Italian centers were collected retrospectively and analyzed. 77 patients were enrolled, corresponding to 86 treatment regimens. The cumulative DRR of IL-1 inhibitors was found to be at 12-, 24-, 48- and 60-month follow-up respectively 79.9, 59.5, 53.5 and 53.5%. No statistically significant difference was found by stratifying for anakinra and canakinumab (p = 0.056) and between patients receiving monotherapy and those being treated with cDMARDs (p = 0.058). On the contrary, significant differences were identified between the group of biologic-naive patients and that of patients previously treated with other biological therapies (p = 0.038) and in relation to the occurrence of adverse events (AE) during therapy (p = 0.04). The study revealed the extraordinary efficacy of IL-1 antagonists in the management of patients with SoJIA.
- Artrite idiopatica giovanile